WE ARE CURRENTLY IN PHASE 3 OF PRODUCT DEVELOPMENT AND WILL BE CONDUCTING A HUMAN FACTORS STUDY NEXT MONTH. WE EXPECT THE LAUNCH OF THE PATI BY NEXT YEAR FOLLOWING FDA CLEARANCE.
EPILEPSY IS THE 3RD LEADING NEUROLOGIC DISORDER IN THE WORLD
welcome to NeuroVice
No more spoons, towels, or pencils. No more pain. No more blood. No more suffering without a solution. FINALLY, MEET PATI, A SEIZURE SOLUTION FOR ORAL HEALTH.
We have finally developed a solution.
Meet PATI, The Protector Against Tongue Injury, developed by a patient for a patient.
PATI is the first, symptom-management, oral device technology that safely and effectively prevents tongue biting and oral trauma during seizures.
PATI’s patent-pending, disposable design prevents dislocation or dislodgment during the episode, allows for natural airflow, and prevents saliva from collecting in the mouth which can lead to choking.
NeuroVice is on a mission to disrupt the current safety guidelines by giving seizure sufferers a safe and effective, first-to-market, solution - PATI.
IT'S EASY TO GET STARTED
The PATI Kit comes with a set of PATIs, a portable container, and a wristband. When you run out of PATIs, simply refill your prescription.
Ashlyn Sanders, CEO & Founder
In 2014, Ashlyn was diagnosed with a rare and life-threatening neurologic condition called a Chiari Malformation, that led to emergent brain surgery and causes seizures. There is no cure for Chiari Malformations. Ashlyn started the company based on her desire to improve the patient experience for millions of others living with seizures.
Ashlyn is a graduate of UNC-Chapel Hill (B.A. Mathematics) and Duke University (M.A. Bioethics and Science Policy). She is also a former 2014 Spring White House Intern during the Obama Administration in The Office of Science and Technology Policy and The Office of Public Engagement. She is passionate about health and health policy and is very active in her community. After getting PATI to market, Ashlyn plans to attend medical school to pursue Neuropsychiatry.